Showing results (61-70 of 90) with videos related to
Sort By:
Pageof 9
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.Molecular and Cellular Biology|June 1, 1994
Repression of cyclin D1: a novel function of MYCA Philipp, A Schneider, I Väsrik, et al.The EMBO Journal|October 2, 1995
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexesP Steiner, A Philipp, J Lukas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancerTomasz M Beer, Kristine M Eilers, Mark Garzotto, et al.Cell|December 24, 1992
Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversionE Reichmann, H Schwarz, E M Deiner, et al.Oncogene|December 22, 1999
DNA binding of USF is required for specific E-box dependent gene activation in vivoA Kiermaier, J M Gawn, L Desbarats, et al.International Journal of Cancer|November 16, 2005
Expression profiling of Wilms tumors reveals new candidate genes for different clinical parametersB Zirn, O Hartmann, B Samans, et al.Oncogene|December 17, 1997
Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexesD Müller, C Bouchard, B Rudolph, et al.Molecular and Cellular Biology|July 1, 1996
Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoterJ Botz, K Zerfass-Thome, D Spitkovsky, et al.BJU International|August 3, 2016
Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placeboJason F Flamiatos, Tomasz M Beer, Julie N Graff, et al.Pageof 9